Acadia Pharmaceuticals
ACAD
ACAD
186 hedge funds and large institutions have $2.25B invested in Acadia Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 63 increasing their positions, 56 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.22% more ownership
Funds ownership: 96.01% → 97.22% (+1.2%)
5% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $25.7M
9% less capital invested
Capital invested by funds: $2.49B → $2.25B (-$236M)
Holders
186
Holding in Top 10
3
Calls
$27.1M
Puts
$25.7M
Top Buyers
| 1 | +$182M | |
| 2 | +$59.3M | |
| 3 | +$45.2M | |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$25.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.2M |
Top Sellers
| 1 | -$32.3M | |
| 2 | -$28M | |
| 3 | -$19M | |
| 4 |
PP
PDT Partners
New York
|
-$10.6M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$9.08M |